DTIL VS SRTS Stock Comparison
Performance
DTIL10/100
10/100
DTIL returned -79.21% in the last 12 months. Based on SPY's performance of -20.66%, its performance is below average giving it a score of 10 of 100.
SRTS10/100
10/100
SRTS returned -74.14% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Sentiment
DTIL68/100
68/100
DTIL had a bullish sentiment score of 68.05% across Twitter and StockTwits over the last 12 months. It had an average of 8.75 posts, 4.76 comments, and 13.29 likes per day.
SRTS65/100
65/100
SRTS had a bullish sentiment score of 64.54% across Twitter and StockTwits over the last 12 months. It had an average of 2.84 posts, 2.38 comments, and 1.78 likes per day.
Technicals
DTIL14/100
14/100
DTIL receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
SRTS21/100
21/100
SRTS receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.
Earnings
DTIL10/100
10/100
DTIL has missed earnings 5 times in the last 20 quarters.
SRTS10/100
10/100
SRTS has missed earnings 6 times in the last 20 quarters.
Profit
DTIL10/100
10/100
Out of the last 20 quarters, DTIL has had 1 profitable quarters and has increased their profits year over year on 1 of them.
SRTS44/100
44/100
Out of the last 20 quarters, SRTS has had 10 profitable quarters and has increased their profits year over year on 5 of them.
Volatility
DTIL32/100
32/100
DTIL has had a lower than average amount of volatility over the last 12 months giving it a score of 32 of 100.
SRTS42/100
42/100
SRTS has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.
Analyst Price Targets
DTIL
"Analyst Price Targets" not found for DTIL
SRTS75/100
75/100
2 analysts offer 12-month price targets for SRTS. Together, they have an average target of 16, the most optimistic target put SRTS at 16 within 12-months and the most pessimistic has SRTS at 16.
All score calculations are broken down here to help you make more informed investing decisions
Precision BioSciences, Inc. Common Stock Summary
Nasdaq / DTIL
Healthcare
Biotechnology
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Sensus Healthcare, Inc Summary
Nasdaq / SRTS
Healthcare
Medical - Devices
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare DTIL to other companies in the same or a similar industry.